Taligen Founders Interviewed on w3w3

Posted in CO Private: Taligen THx

Larry Nelson does fantastic work with w3w3, “Colorado’s Voice of the Technology Community”. Most recently he interviewed Taligen Therapeutics co-founders, CSO V. Michael Holers, MD and President & CEO Woodruff Emlen, MD. Take a listen here to learn more about how Taligen levered their proof-of-concept funding to a $65M Series B financing (HERE). If the [...]

405Taligen+Founders+Interviewed+on+w3w32008-06-02+14%3A58%3A00admin

Taligen Therapeutics: $65M Series B

Posted in CO Private: Taligen THx, Series B

Taligen Therapeutics announced the close of a $65M Series B financing led by Alta Partners and Clarus Ventures and with ongoing participation from existing partners Sanderling Ventures, Tango and High Country Venture.
All I can say is ‘WOW’! I would be willing to bet a dollar that there is not a larger Series B financing [...]

308Taligen+Therapeutics%3A+%2465M+Series+B2008-02-01+16%3A06%3A00admin

Taligen Featured in BioCentury

Posted in CO Private: Taligen THx

Congratulations to Woody Emlen and the rest of the Taligen Therapeutics team on their excellent Emerging Company Profile appearing in yesterday’s BioCentury’s Bernstein Report on BioBusiness. Great coverage not only for Taligen but this widely distributed periodical shines a great light upon Colorado life sciences.
“Taligen Therapeutics, Inc. is taking a two approaches to modulating complement [...]

202Taligen+Featured+in+BioCentury2007-08-14+21%3A23%3A00admin

Web Makeover Wednesday…

Posted in CO Private: Taligen THx, CO S+T Park at Fitz

Two beautiful new Colorado websites can be found…
Taligen Therapeutics, Inc., new website (here), is a development stage biotechnology company with a novel technology to modulate and regulate activation of the complement system. An IND for their lead product, TA106 for persistent asthma, should hopefully be filed by 4Q07.
And at 578 acres, the Fitzsimons Life Science [...]

180Web+Makeover+Wednesday%E2%80%A62007-05-30+14%3A21%3A00admin

Taligen Therapeutics: Meeting Milestones

Posted in CO Private: Taligen THx

Taligen Therapeutics, Inc. announced that it has successfully attained the development milestone required to trigger the funding of the second tranche of its Series A Preferred financing. The $3.75M Series A is led by Sanderling Ventures, Tango and High Country Venture. The milestone was demonstrated in vivo efficacy of its lead compound TA106.
TA106 is a [...]

1132006-08-04+18%3A07%3A00admin

Taligen – Articulating the Complement System

Posted in CO Private: Taligen THx

Co-founders of Taligen Therapeutics, Dr.’s Woody Emlen and Mike Holers recently took home the University of Colorado’s Tech Transfer Office Proof-of-Concept (POC) competition. The POC fund program makes seed stage investments ranging from $50,000 to $100,000 in start-up companies based on promising CU technologies. Each spring and fall a distinguished panel of VC’s contribute to [...]